134 related articles for article (PubMed ID: 19218272)
21. Regulation of donor T cells in the tolerant rats to graft-versus-host disease by FTY720 following small bowel transplantation.
Song J; Ito T; Matsuda C; Tanemura M; Nishida T; Nozawa M; Sawa Y
Transplant Proc; 2006 Dec; 38(10):3181-3. PubMed ID: 17175216
[TBL] [Abstract][Full Text] [Related]
22. CCR5 or CXCR4 use influences the relationship between CD4 cell depletion, NKp44L expression and NK cytotoxicity in SHIV-infected macaques.
Vieillard V; Habib RE; Brochard P; Delache B; Bovendo HF; Calvo J; Morin J; Picq I; Martinon F; Vaslin B; Le Grand R; Debré P
AIDS; 2008 Jan; 22(2):185-92. PubMed ID: 18097220
[TBL] [Abstract][Full Text] [Related]
23. On the Death Rate of Abortively Infected Cells: Estimation from Simian-Human Immunodeficiency Virus Infection.
Ke R; Cong ME; Li D; García-Lerma JG; Perelson AS
J Virol; 2017 Sep; 91(18):. PubMed ID: 28679753
[TBL] [Abstract][Full Text] [Related]
24. FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia in C57/BL6 mice.
Kaudel CP; Schmiddem U; Frink M; Bergmann S; Pape HC; Krettek C; Klempnauer J; Winkler M
Transplant Proc; 2006 Apr; 38(3):679-81. PubMed ID: 16647442
[TBL] [Abstract][Full Text] [Related]
25. Treatment with FTY720 during the induction or effector phase suppresses the development of experimental allergic conjunctivitis in mice.
Sumi T; Fukushima A; Nishino K; Fukuda K; Kumagai N; Nishida T; Ueno H
Cell Biol Int; 2009 Apr; 33(4):534-41. PubMed ID: 19230848
[TBL] [Abstract][Full Text] [Related]
26. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of simian immunodeficiency virus populations in blood and cerebrospinal fluid over the full course of infection.
Harrington PR; Connell MJ; Meeker RB; Johnson PR; Swanstrom R
J Infect Dis; 2007 Oct; 196(7):1058-67. PubMed ID: 17763329
[TBL] [Abstract][Full Text] [Related]
28. FTY720 treatment in experimentally urethane-induced lung tumors.
Lucas da Silva LB; Ribeiro DA; Cury PM; Cordeiro JA; Bueno V
J Exp Ther Oncol; 2008; 7(1):9-15. PubMed ID: 18472638
[TBL] [Abstract][Full Text] [Related]
29. FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia; impact on long-term survival and T-lymphocyte tissue infiltration.
Kaudel CP; Frink M; Schmiddem U; Probst C; Bergmann S; Krettek C; Klempnauer J; van Griensven M; Winkler M
Transplant Proc; 2007 Mar; 39(2):499-502. PubMed ID: 17362767
[TBL] [Abstract][Full Text] [Related]
30. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
31. Preclinical evaluation of the immunomodulatory lymphocyte trafficking drug FTY720 for HIV prevention in the female genital mucosa of macaques.
Morris M; Aubert RD; Butler K; Henning T; Mitchell J; Jenkins L; Garber D; McNicholl J; Kersh EN
J Med Primatol; 2014 Oct; 43(5):370-3. PubMed ID: 25379595
[TBL] [Abstract][Full Text] [Related]
32. Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques.
Ferrantelli F; Buckley KA; Rasmussen RA; Chalmers A; Wang T; Li PL; Williams AL; Hofmann-Lehmann R; Montefiori DC; Cavacini LA; Katinger H; Stiegler G; Anderson DC; McClure HM; Ruprecht RM
Virology; 2007 Feb; 358(1):69-78. PubMed ID: 16996554
[TBL] [Abstract][Full Text] [Related]
33. Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention.
Subbarao S; Ramos A; Kim C; Adams D; Monsour M; Butera S; Folks T; Otten RA
J Med Primatol; 2007 Aug; 36(4-5):238-43. PubMed ID: 17669212
[TBL] [Abstract][Full Text] [Related]
34. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice.
Klingenberg R; Nofer JR; Rudling M; Bea F; Blessing E; Preusch M; Grone HJ; Katus HA; Hansson GK; Dengler TJ
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2392-9. PubMed ID: 17761943
[TBL] [Abstract][Full Text] [Related]
35. FTY720 application following isolated warm liver ischemia improves long-term survival and organ protection in a mouse model.
Kaudel CP; Frink M; van Griensven M; Schmiddem U; Probst C; Bergmann S; Krettek C; Klempnauer J; Winkler M
Transplant Proc; 2007 Mar; 39(2):493-8. PubMed ID: 17362766
[TBL] [Abstract][Full Text] [Related]
36. Immunity in natural SIV infections.
Silvestri G
J Intern Med; 2009 Jan; 265(1):97-109. PubMed ID: 19093963
[TBL] [Abstract][Full Text] [Related]
37. Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine.
Delbridge MS; Shrestha BM; Raftery AT; El Nahas AM; Haylor JL
Transplantation; 2007 Jul; 84(2):187-95. PubMed ID: 17667810
[TBL] [Abstract][Full Text] [Related]
38. FTY720 suppresses the development of colitis in lymphoid-null mice by modulating the trafficking of colitogenic CD4+ T cells in bone marrow.
Fujii T; Tomita T; Kanai T; Nemoto Y; Totsuka T; Sakamoto N; Nakamura T; Tsuchiya K; Okamoto R; Watanabe M
Eur J Immunol; 2008 Dec; 38(12):3290-303. PubMed ID: 19009523
[TBL] [Abstract][Full Text] [Related]
39. Rapid viral decay in simian immunodeficiency virus-infected macaques receiving quadruple antiretroviral therapy.
Brandin E; Thorstensson R; Bonhoeffer S; Albert J
J Virol; 2006 Oct; 80(19):9861-4. PubMed ID: 16973590
[TBL] [Abstract][Full Text] [Related]
40. FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions.
Daniel C; Sartory NA; Zahn N; Schmidt R; Geisslinger G; Radeke HH; Stein JM
Mol Immunol; 2007 Jul; 44(13):3305-16. PubMed ID: 17475330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
